{"hands_on_practices": [{"introduction": "In molecular biology, establishing that a gene causes a specific cellular process is a rigorous undertaking. We must prove not only that the gene is *necessary* for the process to occur but also that it is *sufficient* to trigger the process on its own. This practice challenges you to design a state-of-the-art experiment using CRISPR activation and interference (CRISPRa/i) to definitively test whether the transcription factor ZEB1 is a master regulator of EMT [@problem_id:4886786]. This exercise hones your ability to think like an experimentalist, incorporating critical controls and rescue experiments to build an airtight scientific argument.", "problem": "You are tasked with testing whether Zinc finger E-box-binding homeobox 1 (ZEB1) is sufficient and necessary to drive Epithelial-Mesenchymal Transition (EMT) in a polarized epithelial cell line. You can use Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based transcriptional modulation: CRISPR activation (CRISPRa) to increase transcription and CRISPR interference (CRISPRi) to repress transcription. Sufficiency requires that increasing ZEB1 alone induces EMT in the absence of other EMT stimuli. Necessity requires that reducing ZEB1 prevents EMT when a canonical EMT stimulus is present. Appropriate controls and rescue strategies are needed to attribute causality to ZEB1 and to rule out off-target or nonspecific effects. You must also define readouts to quantify epithelial integrity and mesenchymal transition at both the molecular and functional levels.\n\nWhich option outlines the most rigorous, internally consistent CRISPRa/CRISPRi experimental strategy to test ZEB1 sufficiency and necessity for EMT in a polarized epithelial cell line, including key controls and rescue experiments, and provides scientifically sound readouts?\n\nA. For sufficiency, deliver deactivated Cas9 (dCas9)-based activator (dCas9-VPR or dCas9-p300) with $3$–$4$ non-overlapping single guide RNAs (sgRNAs) tiled across the endogenous ZEB1 promoter and proximal enhancer, in the absence of exogenous stimuli, and measure EMT by decreased E-cadherin (CDH1), increased vimentin (VIM) and fibronectin, loss of apical-basal polarity and tight junction zonula occludens-$1$ (ZO-$1$) continuity, reduced Transepithelial Electrical Resistance (TEER), and increased two-dimensional migration. Include non-targeting sgRNA, “no-sgRNA” dCas9-effector, and safe-harbor locus sgRNA controls, and verify ZEB1 messenger ribonucleic acid (mRNA) and protein induction by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and immunoblot. For necessity, induce EMT with Transforming Growth Factor beta (TGF-$\\beta$) and simultaneously deliver dCas9-Krüppel-associated box (KRAB) CRISPRi with $3$–$4$ sgRNAs targeting the ZEB1 transcription start site window; expect maintenance of epithelial features (TEER preserved, CDH1 sustained, VIM reduced relative to control). Rescue the CRISPRi phenotype by expressing a codon-modified ZEB1 complementary deoxyribonucleic acid (cDNA) from a doxycycline-inducible heterologous promoter lacking the CRISPRi sgRNA binding sites, restoring EMT markers and function despite CRISPRi. As an additional specificity control, attenuate ZEB1 in the CRISPRa condition with CRISPRi to reverse EMT readouts. Perform biological replicates ($n \\geq 3$) and blinded quantification.\n\nB. For sufficiency, apply TGF-$\\beta$ together with dCas9-VPR targeting ZEB1 and claim sufficiency if EMT markers increase more than with TGF-$\\beta$ alone. For necessity, target CRISPRi to VIM to block EMT readouts and conclude that ZEB1 is necessary if VIM decreases. Omit rescue because multiple sgRNAs are used, and rely solely on morphology at $48$ hours.\n\nC. For necessity, use wild-type Cas9 nuclease to knock out ZEB1 coding exons with a single sgRNA and assess only VIM immunofluorescence; for sufficiency, use CRISPRa to activate SNAI1 instead of ZEB1 and infer ZEB1 sufficiency by analogy. Controls include a fluorescent protein overexpression plasmid. No rescue is attempted because knockouts are irreversible.\n\nD. For necessity, perform CRISPRi targeting CDH1 and conclude ZEB1 necessity if epithelial features are lost; for sufficiency, overexpress ZEB1 transiently from a plasmid while maintaining high calcium conditions to preserve junctions, and score only spindle-like morphology. Rescue is performed by re-expressing CDH1 to restore epithelial features, with no assessment of ZEB1 levels or function.", "solution": "The core of the problem is to design an experiment that rigorously tests causality using the paradigms of sufficiency and necessity. A successful design must include specific controls to isolate the variable of interest (ZEB1 expression) and rescue experiments to prove that the observed phenotype is specifically due to the modulation of that variable.\n\n**Option-by-Option Analysis**\n\n**Analysis of Option A:**\n\n- **Sufficiency Test:** The strategy proposes using CRISPRa (dCas9-activator) with multiple single guide RNAs (sgRNAs) to upregulate endogenous ZEB1 *in the absence of exogenous stimuli*. This correctly operationalizes the definition of sufficiency: can ZEB1 expression *alone* drive EMT?\n- **Necessity Test:** The strategy proposes using CRISPRi (dCas9-repressor) to downregulate ZEB1 *while stimulating with TGF-$\\beta$*. This correctly operationalizes the definition of necessity: is ZEB1 required for a canonical inducer (TGF-$\\beta$) to cause EMT?\n- **Technical Rigor:**\n    - The use of $3$–$4$ non-overlapping sgRNAs is a best-practice standard to ensure high on-target efficacy and minimize the probability of off-target effects driving the phenotype.\n    - Targeting the promoter/enhancer for CRISPRa and the transcription start site (TSS) for CRISPRi are the correct genomic locations for these respective technologies.\n- **Controls:** The proposed controls are comprehensive and rigorous.\n    - *Non-targeting sgRNA*: Controls for any non-specific effects of introducing the CRISPR machinery (dCas9-effector + sgRNA).\n    - *“No-sgRNA” dCas9-effector*: Controls for any effects of overexpressing the dCas9-effector protein itself.\n    - *Safe-harbor locus sgRNA*: An excellent control targeting a transcriptionally silent, inert genomic region to provide a baseline.\n    - *On-target validation*: Verifying ZEB1 messenger ribonucleic acid (mRNA) and protein level changes via reverse transcription quantitative polymerase chain reaction (RT-qPCR) and immunoblot is essential to confirm the perturbation worked as intended.\n    - *Reciprocal experiment*: Attenuating ZEB1 with CRISPRi in the CRISPRa-activated cells to reverse the phenotype is a sophisticated and powerful specificity control.\n- **Rescue Strategy:** The proposed rescue is the gold standard. Expressing a *codon-modified ZEB1 complementary deoxyribonucleic acid (cDNA)* that is immune to the CRISPRi sgRNAs from an inducible promoter is the definitive way to prove causality. It shows that re-supplying the ZEB1 protein, and only a ZEB1 variant that cannot be repressed by the CRISPRi machinery, restores the phenotype, thus ruling out off-target effects of the sgRNAs.\n- **Readouts:** The readouts are multifaceted and robust, covering both molecular and functional aspects of EMT.\n    - *Molecular*: Loss of epithelial marker E-cadherin (CDH1) and gain of mesenchymal markers vimentin (VIM) and fibronectin.\n    - *Functional*: Loss of apical-basal polarity (via Zonula Occludens-1 (ZO-1) imaging), loss of barrier function (Transepithelial Electrical Resistance (TEER)), and gain of motility (two-dimensional migration assay).\n- **Statistical Rigor:** The inclusion of biological replicates ($n \\geq 3$) and blinded quantification is critical for a statistically valid and unbiased conclusion.\n\n**Verdict for A:** This option describes an exceptionally rigorous, comprehensive, and logically sound experimental plan that adheres to the highest standards of modern biological research. It correctly tests sufficiency and necessity with all the required controls, rescue strategies, and readouts. **Correct**.\n\n**Analysis of Option B:**\n\n- **Sufficiency Test:** This test is fundamentally flawed. It proposes adding TGF-$\\beta$ along with ZEB1 activation. Sufficiency requires testing the factor *alone*. This design tests for a synergistic or additive effect, not sufficiency.\n- **Necessity Test:** This test is illogical. It proposes targeting VIM with CRISPRi to test for ZEB1 necessity. To test the necessity of ZEB1, one must target the *ZEB1* gene. Targeting a downstream marker like VIM tests the necessity of VIM, not ZEB1.\n- **Controls and Rescue:** It explicitly omits rescue, which is a critical failure. The justification provided is scientifically weak.\n- **Readouts:** Relying only on morphology is insufficient and lacks the quantitative and molecular depth required.\n\n**Verdict for B:** This option contains fundamental errors in experimental logic for both sufficiency and necessity. **Incorrect**.\n\n**Analysis of Option C:**\n\n- **Sufficiency Test:** This part of the experiment is a non-sequitur. It proposes activating SNAI1 to infer ZEB1 sufficiency by \"analogy\". This is not a scientific experiment; to test ZEB1's role, ZEB1 must be the variable.\n- **Necessity Test:** Using a wild-type Cas9 nuclease knockout is a valid approach, but using a single sgRNA is poor practice. More importantly, the problem specifies using the CRISPRa/i framework.\n- **Controls and Rescue:** A fluorescent protein plasmid is not an appropriate control for a CRISPR experiment. The lack of a rescue experiment is a major deficiency.\n- **Readouts:** Assessing only VIM immunofluorescence is an inadequate readout.\n\n**Verdict for C:** The experimental logic is completely invalid, particularly for the sufficiency test. The controls and readouts are insufficient. **Incorrect**.\n\n**Analysis of Option D:**\n\n- **Necessity Test:** The logic is flawed. It suggests targeting CDH1 to test for ZEB1 necessity. ZEB1 is a transcriptional repressor of CDH1. To test ZEB1's necessity in EMT, one must repress ZEB1 during an EMT induction, not repress its downstream target.\n- **Sufficiency Test:** The experimental condition is internally contradictory. Attempting to induce EMT (which involves breaking cell-cell junctions) while simultaneously using high calcium to preserve junctions confounds the experiment and would likely lead to uninterpretable results.\n- **Rescue Strategy:** The \"rescue\" described (re-expressing CDH1) is not a rescue of the primary perturbation (ZEB1 overexpression), but rather an intervention on a downstream effector. This does not prove causality for ZEB1.\n- **Readouts:** Relying solely on morphology is insufficient.\n\n**Verdict for D:** This option is riddled with logical flaws, confounding experimental conditions, and improper rescue and readout strategies. **Incorrect**.\n\n### Conclusion\n\nOption A is the only one that presents a scientifically rigorous, internally consistent, and comprehensive experimental strategy that correctly applies the principles of sufficiency and necessity, incorporating state-of-the-art controls, rescue experiments, and readouts as required by the problem statement.", "answer": "$$\\boxed{A}$$", "id": "4886786"}, {"introduction": "A key outcome of EMT is the acquisition of migratory and invasive capabilities, which are crucial in both development and disease. However, 'motility' is not a single phenomenon; it can mean movement across a surface or invasion through a barrier. This practice asks you to critically evaluate two of the most common laboratory methods for measuring cell movement: the scratch wound assay and the transwell assay [@problem_id:4886765]. By comparing their principles and limitations, you will learn to select the right experimental tool to ask a specific biological question about cell behavior.", "problem": "A research group investigating Epithelial-Mesenchymal Transition (EMT) in the context of both embryonic morphogenesis and carcinoma progression plans to quantify how Transforming Growth Factor-beta (TGF-β) alters epithelial cell motility and invasion. They consider two standard in vitro assays: the scratch wound healing assay on a confluent epithelial monolayer and the transwell (Boyden chamber) assay using porous membranes with and without an Extracellular Matrix (ECM) barrier. Their goals are to: distinguish EMT-associated migration from proliferation-driven wound closure; separate two-dimensional (planar) migration from invasion through an ECM-like barrier; and assess the role of chemotaxis. They also plan to use mitomycin C to suppress proliferation during selected runs.\n\nUsing only fundamental definitions and well-tested facts as a starting point—namely, that EMT reduces epithelial cell-cell adhesion and apical-basal polarity while increasing motility and matrix-interacting behaviors; that migration refers to cell movement over a surface, whereas invasion additionally requires traversal through a barrier resembling basement membrane; that chemotaxis requires a soluble gradient; and that scratch wounds create a cell-free gap in a monolayer while transwells provide a porous membrane that can be optionally coated with a reconstituted basement membrane-like ECM—determine which of the following statements best compares the capabilities and limitations of the scratch wound and transwell assays for quantifying EMT-associated migration and invasion.\n\nA. The scratch wound assay primarily reports collective two-dimensional migration across a free surface and is confounded by proliferation unless an antiproliferative agent or short time windows (e.g., less than $24$ hours) are used; it does not directly assay invasion because there is no barrier to cross, and it does not impose a stable chemotactic gradient. In contrast, the transwell assay primarily reports mostly single-cell movement down a chemoattractant gradient; when the membrane is uncoated it assays migration, and when coated with a basement membrane-like matrix (e.g., Matrigel) it assays invasion. However, transwell readouts depend on pore size (e.g., $8\\,\\mu\\mathrm{m}$), matrix thickness, and do not preserve epithelial junctional context.\n\nB. The scratch wound assay mainly quantifies protease-dependent matrix degradation and invasion because cells must cross a basement membrane-like barrier at the wound edge, whereas the transwell assay primarily measures collective sheet migration without chemotaxis since gradients cannot be established across a porous membrane.\n\nC. Both assays are equivalent measures of invasion if run for $48$ hours without proliferation control, because extended duration ensures that only cells with mesenchymal properties contribute to endpoint readouts.\n\nD. The transwell assay cannot model chemotaxis and therefore only measures random motility, whereas the scratch wound assay provides a stable chemotactic gradient across the wound that cleanly separates migration from proliferation without the need for antiproliferative controls.\n\nChoose the single best answer.", "solution": "The task is to compare the scratch wound and transwell assays based on the provided definitions and research goals.\n\n**Analysis of the Scratch Wound Healing Assay:**\n*   **Principle**: A gap is created in a confluent cell monolayer. The closure of this gap over time is monitored.\n*   **Measurement**: This assay measures the rate of collective cell migration, as the cells move as a sheet to close the \"wound\". This movement is predominantly two-dimensional ($2$D), occurring across the surface of the culture dish.\n*   **Addressing Research Goals**:\n    1.  **Migration vs. Proliferation**: Cell proliferation within the monolayer will also contribute to gap closure, confounding the measurement of migration. As stated in the problem, this necessitates the use of a proliferation inhibitor like mitomycin C or restricting the analysis to short time periods (e.g., less than $24$ hours) before significant cell division occurs.\n    2.  **Migration vs. Invasion**: The definition of invasion requires \"traversal through a barrier\". The scratch assay involves movement across an open, barrier-free surface. Therefore, it measures migration, not invasion.\n    3.  **Chemotaxis**: The definition of chemotaxis requires a \"soluble gradient\". While damaged cells at the edge of the scratch may release factors, this does not create a stable, controlled, or quantifiable chemoattractant gradient. The primary stimulus for movement is the creation of a cell-free space. Thus, the scratch assay is not a suitable method for studying chemotaxis.\n\n**Analysis of the Transwell (Boyden Chamber) Assay:**\n*   **Principle**: A porous membrane separates an upper and lower chamber. Cells are placed in the upper chamber and their movement through the pores to the lower side of the membrane is quantified.\n*   **Measurement**: The assay measures the movement of individual cells, as they must detach from neighbors (if initially confluent) and squeeze through small pores (e.g., $8\\,\\mu\\mathrm{m}$ diameter). It disrupts the `en masse` movement characteristic of an epithelial sheet.\n*   **Addressing Research Goals**:\n    1.  **Migration vs. Proliferation**: The endpoint is the number of cells that have successfully traversed the membrane in a set time (e.g., $6-48$ hours). While cells could proliferate in the top chamber, proliferation is not the direct mechanism of traversal. The assay primarily selects for motile cells.\n    2.  **Migration vs. Invasion**: This assay is uniquely suited to distinguish migration from invasion. When the membrane is uncoated, it measures migration through the pores. When the membrane is coated with a layer of reconstituted basement membrane (e.g., Matrigel), cells must actively degrade and penetrate this ECM barrier to reach the pores. This fulfills the definition of invasion.\n    3.  **Chemotaxis**: This assay is the gold standard for quantifying chemotaxis. By placing a higher concentration of a soluble agent (chemoattractant) in the lower chamber than in the upper chamber, a stable chemical gradient is established across the membrane, providing a directional cue for cell movement. If the agent is at equal concentrations in both chambers, it measures chemokinesis (random motility).\n\n### Option-by-Option Analysis\n\n**A. The scratch wound assay primarily reports collective two-dimensional migration across a free surface and is confounded by proliferation unless an antiproliferative agent or short time windows (e.g., less than $24$ hours) are used; it does not directly assay invasion because there is no barrier to cross, and it does not impose a stable chemotactic gradient. In contrast, the transwell assay primarily reports mostly single-cell movement down a chemoattractant gradient; when the membrane is uncoated it assays migration, and when coated with a basement membrane-like matrix (e.g., Matrigel) it assays invasion. However, transwell readouts depend on pore size (e.g., $8\\,\\mu\\mathrm{m}$), matrix thickness, and do not preserve epithelial junctional context.**\nThis statement accurately summarizes the analysis derived above. It correctly identifies the scratch assay as a measure of collective $2$D migration, notes the confounding effect of proliferation and the lack of an invasion- or chemotaxis-testing capability. It correctly describes the transwell assay's ability to distinguish migration from invasion, its utility for studying chemotaxis, and its nature as a single-cell assay. It also correctly lists critical experimental parameters and limitations, such as pore size and the loss of epithelial context.\n**Verdict: Correct.**\n\n**B. The scratch wound assay mainly quantifies protease-dependent matrix degradation and invasion because cells must cross a basement membrane-like barrier at the wound edge, whereas the transwell assay primarily measures collective sheet migration without chemotaxis since gradients cannot be established across a porous membrane.**\nThis statement contains multiple fundamental errors. The scratch wound assay does *not* involve crossing a basement membrane-like barrier; it is migration on a $2$D surface and thus does not measure invasion. The transwell assay does *not* measure collective sheet migration; it measures individual cell movement. A key strength of the transwell assay is precisely that stable chemical gradients *can* be established across the porous membrane to study chemotaxis.\n**Verdict: Incorrect.**\n\n**C. Both assays are equivalent measures of invasion if run for $48$ hours without proliferation control, because extended duration ensures that only cells with mesenchymal properties contribute to endpoint readouts.**\nThis statement is incorrect. The scratch assay does not measure invasion under any conditions. Running it for $48$ hours without proliferation control makes the results an uninterpretable composite of migration and cell division, not a measure of invasion. The two assays are fundamentally different and are not equivalent measures of anything, let alone invasion.\n**Verdict: Incorrect.**\n\n**D. The transwell assay cannot model chemotaxis and therefore only measures random motility, whereas the scratch wound assay provides a stable chemotactic gradient across the wound that cleanly separates migration from proliferation without the need for antiproliferative controls.**\nThis statement reverses the capabilities of the two assays. The transwell assay is the primary tool *for* modeling chemotaxis. The scratch wound assay does *not* provide a stable chemotactic gradient and is significantly confounded by proliferation, requiring controls.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4886765"}, {"introduction": "The complex behaviors of cells are ultimately governed by the laws of physics, where changes at the molecular level translate into forces that shape tissues. This practice provides a hands-on dive into this concept using a simplified biophysical framework, the Cellular Potts Model (CPM), which is often used in computational simulations of tissue dynamics [@problem_id:4886777]. You will perform a calculation to quantitatively link the decrease in E-cadherin concentration during EMT to the change in cell-cell adhesion energy, predicting how this molecular shift makes it physically easier for a cell to detach from its neighbors.", "problem": "A tissue morphogenesis simulation uses the Cellular Potts Model (CPM) to represent cohesive epithelial cells undergoing Epithelial-Mesenchymal Transition (EMT). In this context, cadherin-mediated adhesion lowers the effective interfacial energy between two adjacent cells, represented by the CPM parameter $J_{cc}$ for a homotypic cell-cell contact. Consider homophilic E-cadherin binding between two apposed cell membranes. Use the following mechanistic base:\n\n1. By the law of mass action for surface binding, the fractional occupancy of cadherin binding sites at surface density $c$ (in molecules per $\\mathrm{\\mu m}^2$) with dissociation constant $K_d$ (same units) is $\\theta = \\dfrac{c}{c + K_d}$.\n\n2. At a cell-cell contact, the probability that a trans bond forms at a given site is the product of the occupancies on the two opposing membranes. For identical cells with the same cadherin density $c$, the bond density per unit area is $n_b = N_{\\max}\\,\\theta^2$, where $N_{\\max}$ is the maximum density of potential binding sites per unit area.\n\n3. Each formed cadherin bond lowers the interfacial energy by $|\\Delta g|$ per bond within an effective interaction width $w$ along the contact, so the adhesion energy reduction per unit boundary length is $|\\Delta g|\\,w\\,n_b$.\n\n4. The effective CPM energy per unit boundary length for a homotypic cell-cell contact is therefore $J_{cc}(c) = J_0 - |\\Delta g|\\,w\\,n_b$, where $J_0$ is the baseline (non-adhesive) interfacial energy per unit length.\n\nNow suppose an EMT-like downregulation reduces the cadherin density from an epithelial value $c_{\\mathrm{epi}}$ to $c_{\\mathrm{EMT}} = f\\,c_{\\mathrm{epi}}$ with $0 < f < 1$. When a small protrusive fluctuation replaces a length $\\Delta L$ of cell-cell contact by the same length of cell-medium contact, the CPM energy changes by $\\Delta E = \\left(J_{cm} - J_{cc}(c)\\right)\\,\\Delta L$, where $J_{cm}$ is the CPM parameter for a cell-medium contact. In a fluctuation-driven CPM dynamics with effective thermal energy $k_B T_{\\mathrm{eff}}$, the relative likelihood of such a fluctuation is weighted by the Boltzmann factor $\\exp\\!\\left(-\\Delta E/\\left(k_B T_{\\mathrm{eff}}\\right)\\right)$.\n\nUsing the data\n- $J_0 = 20$ in units of $k_B T$ per $\\mathrm{\\mu m}$,\n- $J_{cm} = 25$ in units of $k_B T$ per $\\mathrm{\\mu m}$,\n- $|\\Delta g| = 1$ in units of $k_B T$ per bond,\n- $w = 0.02$ in units of $\\mathrm{\\mu m}$,\n- $N_{\\max} = 1000$ in units of sites per $\\mathrm{\\mu m}^2$,\n- $K_d = 200$ in units of molecules per $\\mathrm{\\mu m}^2$,\n- $c_{\\mathrm{epi}} = 600$ in units of molecules per $\\mathrm{\\mu m}^2$,\n- $f = 0.25$ (so $c_{\\mathrm{EMT}} = f\\,c_{\\mathrm{epi}}$),\n- $\\Delta L = 1$ in units of $\\mathrm{\\mu m}$,\n- $k_B T_{\\mathrm{eff}} = 1$ in units of $k_B T$,\n\nderive $J_{cc}(c)$ from first principles using the steps above, then compute the ratio\n$$r = \\frac{\\exp\\!\\left(-\\Delta E_{\\mathrm{EMT}}/\\left(k_B T_{\\mathrm{eff}}\\right)\\right)}{\\exp\\!\\left(-\\Delta E_{\\mathrm{epi}}/\\left(k_B T_{\\mathrm{eff}}\\right)\\right)} = \\exp\\!\\left(-\\frac{\\Delta E_{\\mathrm{EMT}} - \\Delta E_{\\mathrm{epi}}}{k_B T_{\\mathrm{eff}}}\\right),$$\nwhich predicts the fold-change in the likelihood of protrusive replacement of cell-cell by cell-medium interface after EMT relative to the epithelial state.\n\nRound your final numerical answer for $r$ to three significant figures. Express the final answer as a pure number without units.", "solution": "The problem requires the calculation of a ratio, $r$, representing the fold-change in the likelihood of a protrusive event at a cell-cell boundary after Epithelial-Mesenchymal Transition (EMT) relative to the initial epithelial state. The solution proceeds in several steps: first, deriving the expression for the cell-cell adhesion energy parameter $J_{cc}(c)$; second, calculating the relevant quantities for both the epithelial and EMT states; and finally, computing the ratio $r$.\n\nThe problem states that the effective CPM energy per unit boundary length, $J_{cc}(c)$, is given by a baseline energy $J_0$ reduced by an adhesion term. This adhesion term is derived from the density of cadherin bonds at the interface.\nThe fractional occupancy of cadherin binding sites on a single cell surface is given by the law of mass action:\n$$\n\\theta(c) = \\frac{c}{c + K_d}\n$$\nwhere $c$ is the surface density of cadherin and $K_d$ is the dissociation constant.\nFor a contact between two identical cells, the probability of forming a bond at any potential binding site is the product of the occupancies on both membranes, $\\theta^2$. The density of bonds per unit area, $n_b$, is thus:\n$$\nn_b(c) = N_{\\max} \\theta(c)^2 = N_{\\max} \\left(\\frac{c}{c + K_d}\\right)^2\n$$\nwhere $N_{\\max}$ is the maximum density of binding sites.\nEach bond contributes an energy $|\\Delta g|$ over an effective width $w$. The adhesion energy reduction per unit length of the cell-cell contact is therefore $|\\Delta g| w n_b(c)$.\nCombining these, we derive the expression for $J_{cc}(c)$ as requested:\n$$\nJ_{cc}(c) = J_0 - |\\Delta g| w n_b(c) = J_0 - |\\Delta g| w N_{\\max} \\left(\\frac{c}{c + K_d}\\right)^2\n$$\nNext, we calculate the specific values for the epithelial and EMT states. The givens are:\n$c_{\\mathrm{epi}} = 600$ molecules/$\\mathrm{\\mu m}^2$\n$f = 0.25$\n$K_d = 200$ molecules/$\\mathrm{\\mu m}^2$\n$N_{\\max} = 1000$ sites/$\\mathrm{\\mu m}^2$\n$|\\Delta g| = 1$ $k_B T$/bond\n$w = 0.02$ $\\mathrm{\\mu m}$\n$J_0 = 20$ $k_B T$/$\\mathrm{\\mu m}$\n$J_{cm} = 25$ $k_B T$/$\\mathrm{\\mu m}$\n$\\Delta L = 1$ $\\mathrm{\\mu m}$\n$k_B T_{\\mathrm{eff}} = 1$ $k_B T$\n\nThe cadherin density in the EMT state is:\n$$\nc_{\\mathrm{EMT}} = f \\cdot c_{\\mathrm{epi}} = 0.25 \\times 600 = 150 \\text{ molecules}/\\mathrm{\\mu m}^2\n$$\nNow, we calculate the fractional occupancies for both states:\n$$\n\\theta_{\\mathrm{epi}} = \\frac{c_{\\mathrm{epi}}}{c_{\\mathrm{epi}} + K_d} = \\frac{600}{600 + 200} = \\frac{600}{800} = \\frac{3}{4}\n$$\n$$\n\\theta_{\\mathrm{EMT}} = \\frac{c_{\\mathrm{EMT}}}{c_{\\mathrm{EMT}} + K_d} = \\frac{150}{150 + 200} = \\frac{150}{350} = \\frac{3}{7}\n$$\nThe corresponding bond densities are:\n$$\nn_{b, \\mathrm{epi}} = N_{\\max} \\theta_{\\mathrm{epi}}^2 = 1000 \\times \\left(\\frac{3}{4}\\right)^2 = 1000 \\times \\frac{9}{16} = \\frac{9000}{16} = 562.5 \\text{ bonds}/\\mathrm{\\mu m}^2\n$$\n$$\nn_{b, \\mathrm{EMT}} = N_{\\max} \\theta_{\\mathrm{EMT}}^2 = 1000 \\times \\left(\\frac{3}{7}\\right)^2 = 1000 \\times \\frac{9}{49} = \\frac{9000}{49} \\text{ bonds}/\\mathrm{\\mu m}^2\n$$\nThe ratio $r$ is given by:\n$$\nr = \\exp\\left(-\\frac{\\Delta E_{\\mathrm{EMT}} - \\Delta E_{\\mathrm{epi}}}{k_B T_{\\mathrm{eff}}}\\right)\n$$\nThe energy change for replacing a length $\\Delta L$ of cell-cell contact with cell-medium contact is $\\Delta E(c) = (J_{cm} - J_{cc}(c))\\Delta L$.\nThe difference in energy changes is:\n$$\n\\Delta E_{\\mathrm{EMT}} - \\Delta E_{\\mathrm{epi}} = \\left( (J_{cm} - J_{cc}(c_{\\mathrm{EMT}})) - (J_{cm} - J_{cc}(c_{\\mathrm{epi}})) \\right) \\Delta L\n$$\n$$\n\\Delta E_{\\mathrm{EMT}} - \\Delta E_{\\mathrm{epi}} = \\left( J_{cc}(c_{\\mathrm{epi}}) - J_{cc}(c_{\\mathrm{EMT}}) \\right) \\Delta L\n$$\nSubstituting the expression for $J_{cc}(c)$:\n$$\nJ_{cc}(c_{\\mathrm{epi}}) - J_{cc}(c_{\\mathrm{EMT}}) = \\left(J_0 - |\\Delta g| w n_{b, \\mathrm{epi}}\\right) - \\left(J_0 - |\\Delta g| w n_{b, \\mathrm{EMT}}\\right)\n$$\n$$\nJ_{cc}(c_{\\mathrm{epi}}) - J_{cc}(c_{\\mathrm{EMT}}) = |\\Delta g| w (n_{b, \\mathrm{EMT}} - n_{b, \\mathrm{epi}})\n$$\nTherefore, the exponent's argument is simplified:\n$$\n\\Delta E_{\\mathrm{EMT}} - \\Delta E_{\\mathrm{epi}} = |\\Delta g| w (n_{b, \\mathrm{EMT}} - n_{b, \\mathrm{epi}}) \\Delta L\n$$\nSubstituting the numerical values (note that the units of energy ($k_B T$), length ($\\mu$m), etc., are consistent, and with $k_B T_{\\mathrm{eff}} = 1 \\, k_B T$, the exponent is dimensionless as required):\n$$\nn_{b, \\mathrm{EMT}} - n_{b, \\mathrm{epi}} = \\frac{9000}{49} - 562.5 = \\frac{9000}{49} - \\frac{1125}{2} = \\frac{18000 - 55125}{98} = -\\frac{37125}{98}\n$$\n$$\n\\Delta E_{\\mathrm{EMT}} - \\Delta E_{\\mathrm{epi}} = (1) \\times (0.02) \\times \\left(-\\frac{37125}{98}\\right) \\times (1) = \\frac{1}{50} \\times \\left(-\\frac{37125}{98}\\right) = -\\frac{742.5}{98} = -\\frac{1485}{196}\n$$\nThe value of the difference is approximately $-7.5765$. Since $k_B T_{\\mathrm{eff}} = 1$, this is the value of the numerator in the exponent for $r$.\nThe ratio $r$ is then:\n$$\nr = \\exp\\left(-\\frac{-\\frac{1485}{196}}{1}\\right) = \\exp\\left(\\frac{1485}{196}\\right)\n$$\nNumerically, this is:\n$$\nr \\approx \\exp(7.5765306) \\approx 1951.755\n$$\nRounding the final answer to three significant figures gives $1950$ or $1.95 \\times 10^3$.", "answer": "$$\\boxed{1.95 \\times 10^{3}}$$", "id": "4886777"}]}